Muhammad Wazir, Faaruq Shafqat, Hussain Amjad, Kakakhail M Basim, Fatmi Shahab
Institute of Nuclear Medicine Oncology and Radiotherapy, PO Box 110, Abbottabad, NWFP, Pakistan.
Radiat Prot Dosimetry. 2008;128(1):90-7. doi: 10.1093/rpd/ncm243. Epub 2007 May 27.
Radioiodine (131 I) therapy has been in use for more than 60 y. Several protocols have been suggested and used for prescribing the activity to be administered to the patients for the treatment of hyperthyroidism; application of these protocols may result in an under or over dose of the hyperthyroid patients. The main objective of this study was to carry out quantitative analysis of the factors responsible for possible under or over dosage of the patients. In this regard, a total of 59 patients [15 diffuse goitre (DG) and 44 nodular goitre (NG) cases] were studied. In order to compare the thyroid doses calculated by using different protocols, the dosimetric approach was followed. 131 I uptakes were measured after 24 and 48 h, respectively, by giving 0.5 MBq of 131 I to each patient. Thyroid mass and effective half-life were also calculated for each patient and the variations in the thyroid doses were analysed. According to the results 28 and 54% patients were under dosed and 72 and 46% patients were over dosed with DG and NG, respectively. The protocols, which have not taken into account the thyroid mass, multi pre-therapeutic 131 I uptakes and the effective half-life of 131 I of the individual patient, showed a higher degree of deviation from the required thyroid dose. Besides these parameters, some fundamental factors such as radiosensitivity, previous exposure to thyroid drugs and duration of the disease are recommended to be incorporated, which can certainly affect the clinical out comes.
放射性碘(131I)治疗已应用超过60年。已经提出并使用了几种方案来确定给予甲亢患者的治疗活度;应用这些方案可能导致甲亢患者的剂量不足或过量。本研究的主要目的是对可能导致患者剂量不足或过量的因素进行定量分析。在这方面,共研究了59例患者[15例弥漫性甲状腺肿(DG)和44例结节性甲状腺肿(NG)]。为了比较使用不同方案计算的甲状腺剂量,采用了剂量测定方法。分别给每位患者服用0.5MBq的131I后,在24小时和48小时测量131I摄取量。还计算了每位患者的甲状腺质量和有效半衰期,并分析了甲状腺剂量的变化。结果显示,DG组和NG组分别有28%和54%的患者剂量不足,72%和46%的患者剂量过量。未考虑甲状腺质量、多次治疗前131I摄取量以及个体患者131I有效半衰期的方案,与所需甲状腺剂量的偏差程度更高。除了这些参数外,还建议纳入一些基本因素,如放射敏感性、既往甲状腺药物暴露情况和疾病持续时间,这些因素肯定会影响临床结果。